CDKN2A deletion
|
B Acute Lymphoblastic Leukemia
|
CDKN2A deletion
|
B Acute Lymphoblastic Leukemia
|
blinatumomab Sensitive: C3 – Early Trials
|
blinatumomab Sensitive: C3 – Early Trials
|
CDKN2A deletion
|
Mantle Cell Lymphoma
|
CDKN2A deletion
|
Mantle Cell Lymphoma
|
ibrutinib Resistant: C3 – Early Trials
|
ibrutinib Resistant: C3 – Early Trials
|
CDKN2A deletion
|
ALL
|
CDKN2A deletion
|
ALL
|
blinatumomab Sensitive: C3 – Early Trials
|
blinatumomab Sensitive: C3 – Early Trials
|
CDKN2A deletion
|
Melanoma
|
CDKN2A deletion
|
Melanoma
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
CDKN2A deletion
|
Gallbladder Cancer
|
CDKN2A deletion
|
Gallbladder Cancer
|
palbociclib Resistant: C3 – Early Trials
|
palbociclib Resistant: C3 – Early Trials
|
CDKN2A deletion
|
Glioma
|
CDKN2A deletion
|
Glioma
|
vincristine + lomustine + procarbazine hydrochloride Resistant: C3 – Early Trials
|
vincristine + lomustine + procarbazine hydrochloride Resistant: C3 – Early Trials
|
CDKN2A deletion
|
HCC
|
CDKN2A deletion
|
HCC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
CDKN2A deletion
|
Melanoma
|
CDKN2A deletion
|
Melanoma
|
palbociclib Sensitive: C3 – Early Trials
|
palbociclib Sensitive: C3 – Early Trials
|
CDKN2A deletion
|
Pancreatic Cancer
|
CDKN2A deletion
|
Pancreatic Cancer
|
palbociclib Resistant: C3 – Early Trials
|
palbociclib Resistant: C3 – Early Trials
|
CDKN2A deletion
|
Gastric Adenocarcinoma
|
CDKN2A deletion
|
Gastric Adenocarcinoma
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
CDKN2A deletion
|
Diffuse Large B Cell Lymphoma
|
CDKN2A deletion
|
Diffuse Large B Cell Lymphoma
|
T-lymphocyte cell therapy Resistant: C3 – Early Trials
|
T-lymphocyte cell therapy Resistant: C3 – Early Trials
|
CDKN2A deletion
|
Prolymphocytic Leukemia
|
CDKN2A deletion
|
Prolymphocytic Leukemia
|
alemtuzumab Resistant: C4 – Case Studies
|
alemtuzumab Resistant: C4 – Case Studies
|
CDKN2A deletion
|
Estrogen Receptor Positive Breast Cancer
|
CDKN2A deletion
|
Estrogen Receptor Positive Breast Cancer
|
palbociclib + VRx-510 Sensitive: D – Preclinical
|
palbociclib + VRx-510 Sensitive: D – Preclinical
|
CDKN2A deletion
|
Estrogen Receptor Positive Breast Cancer
|
CDKN2A deletion
|
Estrogen Receptor Positive Breast Cancer
|
ribociclib + VRx-510 Sensitive: D – Preclinical
|
ribociclib + VRx-510 Sensitive: D – Preclinical
|
CDKN2A deletion
|
Ewing Sarcoma
|
CDKN2A deletion
|
Ewing Sarcoma
|
ASP7487 Sensitive: D – Preclinical
|
ASP7487 Sensitive: D – Preclinical
|
CDKN2A deletion
|
Ewing Sarcoma
|
CDKN2A deletion
|
Ewing Sarcoma
|
palbociclib Sensitive: D – Preclinical
|
palbociclib Sensitive: D – Preclinical
|
CDKN2A deletion
|
RCC
|
CDKN2A deletion
|
RCC
|
temsirolimus Sensitive: D – Preclinical
|
temsirolimus Sensitive: D – Preclinical
|
CDKN2A deletion
|
Pancreatic Ductal Adenocarcinoma
|
CDKN2A deletion
|
Pancreatic Ductal Adenocarcinoma
|
BET inhibitor + CDK inhibitor Sensitive: D – Preclinical
|
BET inhibitor + CDK inhibitor Sensitive: D – Preclinical
|
CDKN2A deletion
|
HER2 Positive Breast Cancer
|
CDKN2A deletion
|
HER2 Positive Breast Cancer
|
abemaciclib + tucatinib Sensitive: D – Preclinical
|
abemaciclib + tucatinib Sensitive: D – Preclinical
|
CDKN2A deletion
|
Pancreatic Ductal Adenocarcinoma
|
CDKN2A deletion
|
Pancreatic Ductal Adenocarcinoma
|
palbociclib + JQ-1 Sensitive: D – Preclinical
|
palbociclib + JQ-1 Sensitive: D – Preclinical
|